Developing medical countermeasures against emerging pathogens like COVID-19
Biocontainment Research Support Service(s) Core
['FUNDING_OTHER'] · UNIVERSITY OF MISSOURI-COLUMBIA · NIH-10910193
This study is working on developing new vaccines and treatments for diseases like COVID-19 to help keep everyone safe, using advanced science techniques to test these solutions in a secure environment.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MISSOURI-COLUMBIA (nih funded) |
| Locations | 1 site (COLUMBIA, UNITED STATES) |
| Trial ID | NIH-10910193 on ClinicalTrials.gov |
What this research studies
This research focuses on providing essential resources for the pre-clinical development of medical countermeasures targeting emerging and re-emerging pathogens, particularly those that pose a threat to public health, such as COVID-19. The Biocontainment Research Support Services Core (BRSSC) utilizes advanced techniques in aerobiology, animal modeling, immunology, imaging, and microbiology to evaluate novel vaccines, treatments, and diagnostics. Patients may benefit indirectly as the research aims to enhance the safety and efficacy of medical interventions against infectious diseases. The BRSSC operates under strict biocontainment conditions to ensure the safe handling of pathogens during experimentation.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals at risk of exposure to emerging pathogens or those affected by COVID-19.
Not a fit: Patients with established immunity to COVID-19 or those not at risk of exposure to infectious diseases may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines and treatments for COVID-19 and other emerging infectious diseases.
How similar studies have performed: Other research initiatives focusing on similar biocontainment strategies have shown promise in developing effective medical countermeasures against infectious diseases.
Where this research is happening
COLUMBIA, UNITED STATES
- UNIVERSITY OF MISSOURI-COLUMBIA — COLUMBIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OLSON, RACHEL M — UNIVERSITY OF MISSOURI-COLUMBIA
- Study coordinator: OLSON, RACHEL M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.